Chimeric antigen receptor T cell therapy for autoimmune disease

James Chung, Jennifer N. Brudno(National Institutes of Health), Dominic Borie, James N. Kochenderfer(National Institutes of Health)

Nature reviews. Immunology

June 3, 2024

10.1038/s41577-024-01035-3

Cited by 111Open Access

Abstract

Related Papers

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

Adrienne H. Long, Waleed Haso, Jack F. Shern et al.|Nature Medicine|2015|1.8k

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

James N. Kochenderfer, Mark E. Dudley, Steven A. Feldman et al.|Blood|2011|1.4k

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

Brad H. Rovin, Richard Furie, Kevin Latinis et al.|Arthritis & Rheumatism|2012|1.4k

CD25+ CD4+ T Cells, Expanded with Dendritic Cells Presenting a Single Autoantigenic Peptide, Suppress Autoimmune Diabetes

Kristin V. Tarbell, Sayuri Yamazaki, Kara Olson et al.|The Journal of Experimental Medicine|2004|728

Chimeric Receptors Providing Both Primary and Costimulatory Signaling in T Cells from a Single Gene Product

Helene M. Finney, Alastair D. G. Lawson, Christopher Bebbington et al.|The Journal of Immunology|1998|540